Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Change In Receivables : HK$44 Mil (TTM As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) Change In Receivables?

Dawnrays Pharmaceutical (Holdings)'s change in receivables for the quarter that ended in Dec. 2024 was HK$15 Mil. It means Dawnrays Pharmaceutical (Holdings)'s Accounts Receivable declined by HK$15 Mil from Jun. 2024 to Dec. 2024 .

Dawnrays Pharmaceutical (Holdings)'s change in receivables for the fiscal year that ended in Dec. 2024 was HK$43 Mil. It means Dawnrays Pharmaceutical (Holdings)'s Accounts Receivable declined by HK$43 Mil from Dec. 2023 to Dec. 2024 .

Dawnrays Pharmaceutical (Holdings)'s Accounts Receivable for the quarter that ended in Dec. 2024 was HK$131 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Dawnrays Pharmaceutical (Holdings)'s Days Sales Outstanding for the six months ended in Dec. 2024 was 46.22.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Dawnrays Pharmaceutical (Holdings)'s liquidation value for the six months ended in Dec. 2024 was HK$991 Mil.

Dawnrays Pharmaceutical (Holdings) Change In Receivables Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) Change In Receivables Chart

Dawnrays Pharmaceutical (Holdings) Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

47.71

-33.15

-89.13

80.27

43.48

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-134.63	5.57	74.69	28.23	15.49

Dawnrays Pharmaceutical (Holdings) Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$44 Mil.

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Dawnrays Pharmaceutical (Holdings)'s Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	130.574	/	515.538	*	91
=	46.22

2. In Ben Graham's calculation of liquidation value, Dawnrays Pharmaceutical (Holdings)'s accounts receivable are only considered to be worth 75% of book value:

Dawnrays Pharmaceutical (Holdings)'s liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1457.795	-	728.801	+	0.75 * 130.574	+	0.5 * 329.1
=	991

Dawnrays Pharmaceutical (Holdings) Change In Receivables Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Dawnrays Pharmaceutical (Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » Change In Receivables

Traded in Other Exchanges

N/A

Address

338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG

Website

https://www.dawnrays.com

Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.

Executives

Li Kei Ling
Hung Yung Lai
Fortune United Group Limited	2101 Beneficial owner
Hunwick International Limited	2201 Interest of corporation controlled by you
Keysmart Enterprises Limited	2201 Interest of corporation controlled by you
Iu Pun	2202 Interest of your spouse
Li Tung Ming
Fmr Llc	2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines